131674-39-0

Basic information

• Product Name: 1-(2-chloropyridin-3-yl)ethanol
• Synonyms: 1-(2-chloropyridin-3-yl)ethanol;2-Chloro-a-Methyl-3-pyridineMethanol;2-chloro-3-(1-hydroxyethyl)pyridine;3-PYRIDINEMETHANOL, 2-CHLORO-α-METHYL-
• CAS NO: 131674-39-0
• Molecular Formula: C₇H₈ClNO
• Molecular Weight: 157.59752
• Mol File: 131674-39-0.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1-(2-chloropyridin-3-yl)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-chloropyridin-3-yl)ethanol(131674-39-0)
• EPA Substance Registry System: 1-(2-chloropyridin-3-yl)ethanol(131674-39-0)

Safety Data

• Hazardous Substances Data: 131674-39-0(Hazardous Substances Data)

Usage

General Description

1-(2-chloropyridin-3-yl)ethanol, also known as 2-chloro-3-pyridyl ethanol, is a chemical compound with the molecular formula C7H8ClNO. It is a white to light yellow crystalline solid that is used as a building block in the synthesis of various pharmaceutical and agrochemical products. 1-(2-chloropyridin-3-yl)ethanol is classified as an alcohol and contains a chloropyridinyl group, which gives it its characteristic properties and reactivity. It is commonly used as a reagent in organic synthesis and as an intermediate in the production of active pharmaceutical ingredients. Additionally, it is an important chemical in the study and development of new drug compounds. Overall, 1-(2-chloropyridin-3-yl)ethanol is a versatile compound with a wide range of applications in the field of organic chemistry and pharmaceutical research.

Upstream product

• 109-09-1 2-chloropyridine 
• 75-07-0 acetaldehyde 
• 75-16-1 methylmagnesium bromide 
• 36404-88-3 2-chloro-3-carbaldehydepyridine 

Downstream Products

• 1314734-68-3 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde 
• 916325-83-2 pyrazolo[3,4-b]pyridine-3-carboxylic acid methyl ester 
• 116855-08-4 1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid 
• 877770-64-4 1-(2,4-dichlorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid methyl ester 
• 116834-96-9 3-methyl-1H-pyrazolo[3,4b]pyridine 
• 131674-40-3 1-(2-methoxypyridin-3-yl)ethanone 
• 65326-33-2 1-(2-amino-3-pyridinyl)-1-ethanone 
• 62838-65-7 1-(2-hydroxypyridin-3-yl)ethanone 
• 55676-21-6 3-acetyl-2-chloropyridine 
• 1314734-59-2 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde 
• 916325-85-4 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid 
• 916325-84-3 methyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylate 

Relevant articles and documents

PRMT5 INHIBITORS

The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases.